MS Clinician Blood Monitoring Survey

Start of Block: Default Question Block

Q3 Province:

▼ British Columbia (1) ... Yukon (13)

Q4 Training

* Neurologist (1)
* Medical Doctor (non-neurologist) (2)
* Registered Nurse (3)
* Nurse Practitioner (4)

Q5 How many Multiple Sclerosis (MS) patients do you follow?

* < 500 (1)
* 500-1000 (2)
* > 1000 (3)

Q6 How many years have you been practicing?

* 0-5 (1)
* 5-10 (2)
* 10-15 (3)
* > 15 (4)

Q7 Do you prescribe MS disease modifying therapies?

* Yes (1)
* No (2)

Skip To: Q9 If Do you prescribe MS disease modifying therapies? = No

Q8 Please rate your level of concern with lab monitoring for the following Health Canada-Approved Drugs for MS:

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | Not Concerned (1) | Somewhat Concerned (2) | Very Concerned (3) | Do NOT prescribe (4) |
| Interferon (Avonex, Betaseron, Extavia, Rebif) (1) |  |  |  |  |
| Glatiramer (Copaxone 20 or 40) (2) |  |  |  |  |
| Teriflunomide (Aubagio) (3) |  |  |  |  |
| Dimethyl Fumarate (Tecfidera) (4) |  |  |  |  |
| Cladribine (Mavenclad) (5) |  |  |  |  |
| Fingolimod (Gilenya) (6) |  |  |  |  |
| Natalizumab (Tysabri) (7) |  |  |  |  |
| Ocrelizumab (Ocrevus) (8) |  |  |  |  |
| Alemtuzumab (Lemtrada) (9) |  |  |  |  |
| Daclizumab (Zynbryta) (10) |  |  |  |  |

Q9 Do you receive lab results on paper?

* Yes, all paper (1)
* Mostly paper (2)
* Some paper (3)
* Paperless (4)

Q10 Do you manage your MS clinic using an EMR (electronic medical record)?

* Yes (1)
* No (2)

Skip To: Q12 If Do you manage your MS clinic using an EMR (electronic medical record)? = No

Q11 Does your EMR receive lab results from Excelleris?

* Yes (1)
* No (2)

Q12 What systems do you have in place to monitor lab results? Select all that apply

* Patient Support Program (1)
* RN-led Team (2)
* Medical Office Assistant Team (3)
* EMR Alerts (4)
* Other, please specifiy: (5) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q13 How often do you review lab results Monday to Friday?

* Daily or almost daily (1)
* 2-3 times per week (2)
* Once per week or less (3)

Q14 How much time do you spend reviewing lab results per week?

* Less than an hour per week (1)
* 1-2 hours per week (2)
* 2-3 hours per week (3)
* More than 3 hours per week (4)

Q15 How often do you review lab results on weekends?

* Never (1)
* Some ( (2)
* Most Weekends (=/> 50% of weekends) (3)

Q16 Do you have coverage for reviewing lab results on weekends/holidays?

* Yes (1)
* No (2)

Q17 In general, when you review lab results for your patients, how do you know what treatment they are taking?

* EMR (1)
* Memory (2)
* Retrieve paper chart (3)
* I pass abnormal results off to a team member (4)
* Other, please specify: (5) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

Q18 Who **primarily** ensures that patients are completing lab tests as recommended?

* Medical Doctor (1)
* Registered Nurse (2)
* Nurse Practitioner (3)
* Medical Office Assistant (4)
* Patient Support Program (5)
* Patient responsibility (6)

Q19 For MS patients on therapy where risk mitigation is not a part of the patient support program, how do you know if a patient is NON-ADHERENT to the lab monitoring process?

* Registered Nurse (1)
* Nurse Practitioner (2)
* Medical Office Assistant (3)
* Informed by Patient (4)
* I don't know (5)

Q20 Overall, what is your perception of the performance of your laboratory monitoring process?

* Our lab monitoring process: 1) ensures that monitoring blood work is completed, and 2) abnormal blood work is appropriately identified and acted upon (1)
* There are some instances where our lab monitoring process has failed (2)
* I am aware of instances where our lab monitoring process has had a negative effect on patient outcomes (3)

Q21 Please identify whether or not any of the following factors have impacted the effectiveness of your blood monitoring program (Never = 0%, Rarely = 1%-10%, Commonly >/=10%):

|  |  |  |  |
| --- | --- | --- | --- |
|  | Never (1) | Rarely (2) | Commonly (3) |
| Errors on laboratory requisitions (eg. Incorrect name, aliases, PHN, copy to providers or tests ordered) (1) |  |  |  |
| Patient non-compliance with lab testing (2) |  |  |  |
| Errors in collection of samples (eg. unusable samples, clotted samples, lost samples, undetermined results) (3) |  |  |  |
| Errors in data sent from the lab (eg. wrong provider attributed to tests, sent to wrong physician, incomplete results, wrong provider information, missing lab work) (4) |  |  |  |
| Administrative errors in getting results to physicians for review (eg. faxing, filing errors) (5) |  |  |  |
| Errors in interpreting data or acting on data in the context of patient care (eg. failure to recognize meaningfully abnormal bloodwork, errors in alerting patient of abnormal or critical results, errors of referral and definitive treatment) (6) |  |  |  |

Q22 What is your perception of the overall risk in the blood monitoring process for Lemtrada?

* Minimal risk (1)
* Moderate risk (2)
* High risk (3)

Q23 Have your Lemtrada patients experienced critical lab results such as thrombocytopenia or kidney damage?

* Yes, if yes please specify (1) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
* No (2)

Q24 Were there any delays to identification and treatment?

* Yes, if yes please specify (1) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
* No (2)

Q25 Does the existing infrastructure for Lemtrada monitoring impact your comfort level of recommending this treatment?

* Yes, if yes please specify (1) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_
* No (2)

Q26 Would an automated blood monitoring system impact your use of Lemtrada?

* Probably (1)
* Maybe (2)
* No (3)
* Don't know (4)
* Other, please specify (5) \_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_\_

End of Block: Default Question Block